Employment status and health related quality of life among Hodgkin-lymphoma survivors’– results based on data from a major treatment center in Hungary

Table 4 Predictors for treatment related long-term side effects

	Treatment related long- term side effects	No treatment related long-term side effects	P
Gender
Male (n = 69)	28 (41%)	41 (59%)	0.011
Female (n = 71)	44 (62%)	27 (38%)	0.011
Chemotherapy
A(E)BVD (n = 95)	38 (40%)	57 (60%)	<0.001
Other than ABVD (n = 43)	33 (77%)	10 (23%)	<0.001

A(E)BVD: adriamycin, (epirubicin), bleomycin, vinblastine and dacarbazine; Other than ABVD: CV(O)PP:cyclophosphamide, vinblastine [vincristine], procarbazine and prednisolone; COPP/ABV:cyclophosphamide, vincristine, procarbazine, prednisolone/adriamycin, bleomycin and vinblastine

ISSN: 1477-7525